Metastasis in renal cell carcinoma: Biology and implications for therapy

被引：117

作者：

Gong, Jun ^{[1
]}

Maia, Manuel Caitano ^{[2
]}

Dizman, Nazli ^{[3
]}

Govindarajan, Ameish ^{[1
]}

Pal, Sumanta K. ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

[2] Inst Hemomed Oncol & Hematol, Div Med Oncol, Ave Arnolfo de Azevedo,121 Cerqueira Cesar, BR-01248040 Sao Paulo, Brazil

[3] Istanbul Medeniyet Univ, Dept Internal Med, Goztepe Res & Training Hosp, Istanbul, Turkey

来源：

ASIAN JOURNAL OF UROLOGY | 2016年 / 3卷 / 04期

关键词：

Renal cell carcinoma; Metastasis; Vascular endothelial growth factor; Mammalian target of rapamycin; Hypoxia inducible factor;

D O I：

10.1016/j.ajur.2016.08.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.

引用

页码：286 / 292

页数：7

共 42 条

[1] MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Aubert, Sebastien
Fauquette, Valerie
Hemon, Brigitte
Lepoivre, Rejane
Briez, Nicolas
Bernard, David
Van Seuningen, Isabelle
Leroy, Xavier
Perrais, Michael
[J]. CANCER RESEARCH, 2009, 69 (14) : 5707 - 5715
[2] Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
Bianchi, M.
Sun, M.
Jeldres, C.
Shariat, S. F.
Trinh, Q. -D.
Briganti, A.
Tian, Z.
Schmitges, J.
Graefen, M.
Perrotte, P.
Menon, M.
Montorsi, F.
Karakiewicz, P. I.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (04) : 973 - 980
[3] Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Callea, Marcella
Albiges, Laurence
Gupta, Mamta
Cheng, Su-Chun
Genega, Elizabeth M.
Fay, Andre P.
Song, Jiaxi
Carvo, Ingrid
Bhatt, Rupal S.
Atkins, Michael B.
Hodi, F. Stephen
Choueiri, Toni K.
McDermott, David F.
Freeman, Gordon J.
Signoretti, Sabina
[J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1158 - 1164
[4] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Choueiri, Toni K.
Escudier, Bernard
Powles, Thomas
Tannir, Nizar M.
Mainwaring, Paul N.
Rini, Brian I.
Hammers, Hans J.
Donskov, Frede
Roth, Bruce J.
Peltola, Katriina
Lee, Jae Lyun
Heng, Daniel Y. C.
Schmidinger, Manuela
Agarwal, Neeraj
Sternberg, Cora N.
McDermott, David F.
Aftab, Dana T.
Hessel, Colin
Old, Christian Scheff
Schwab, Gisela
Hutson, Thomas E.
Pal, Sumanta
Motzer, Robert J.
[J]. LANCET ONCOLOGY, 2016, 17 (07) : 917 - 927
[5] The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, Caleb F.
Ricketts, Christopher J.
Wang, Min
Yang, Lixing
Cherniack, Andrew D.
Shen, Hui
Buhay, Christian
Kang, Hyojin
Kim, Sang Cheol
Fahey, Catherine C.
Hacker, Kathryn E.
Bhanot, Gyan
Gordenin, Dmitry A.
Chu, Andy
Gunaratne, Preethi H.
Biehl, Michael
Seth, Sahil
Kaipparettu, Benny A.
Bristow, Christopher A.
Donehower, Lawrence A.
Wallen, Eric M.
Smith, Angela B.
Tickoo, Satish K.
Tamboli, Pheroze
Reuter, Victor
Schmidt, Laura S.
Hsieh, James J.
Choueiri, Toni K.
Hakimi, A. Ari
Chin, Lynda
Meyerson, Matthew
Kucherlapati, Raju
Park, Woong-Yang
Robertson, A. Gordon
Laird, Peter W.
Henske, Elizabeth P.
Kwiatkowski, David J.
Park, Peter J.
Morgan, Margaret
Shuch, Brian
Muzny, Donna
Wheeler, David A.
Linehan, W. Marston
Gibbs, Richard A.
Rathmell, W. Kimryn
Creighton, Chad J.
Signoretti, Sabina
Seiler, Michael
Chao, Hsu
Dahdouli, Mike
[J]. CANCER CELL, 2014, 26 (03) : 319 - 330
[6] Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors
Dudek, Arkadiusz Z.
Raza, Ahmad
Chi, Ming
Singhal, Meghali
Oberoi, Rajneet
Mittapalli, Rajendar K.
Agarwal, Sagar
Elmquist, William F.
[J]. CLINICAL GENITOURINARY CANCER, 2013, 11 (02) : 155 - 160
[7] Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma
Eggener, Scott E.
Yossepowitch, Ofer
Kundu, Shilajit
Motzer, Robert J.
Russo, Paul
[J]. JOURNAL OF UROLOGY, 2008, 180 (03) : 873 - 878
[8] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
Escudier, Bernard J.
Powles, Thomas
Motzer, Robert J.
Olencki, Thomas
Aren, Osvaldo Rudy
Oudard, Stephane
Bracarda, Sergio
Tomczak, Piotr
Castellano, Daniel E.
Appleman, Leonard Joseph
Drabkin, Harry A.
Vaena, Daniel A.
Milwee, Steven
Youkstetter, Jillian
Choueiri, Toni K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, James
Ko, Jennifer
Rini, Brian
Rayman, Pat
Ireland, Joanna
Cohen, Peter
[J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (07) : 856 - 861
[10] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
FYFE, G
FISHER, RI
ROSENBERG, SA
SZNOL, M
PARKINSON, DR
LOUIE, AC
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 688 - 696

← 1 2 3 4 5 →